This correlation has been independently confirmed by a recent report demonstrating that stathmin was overexpressed in 84% of 131 high-grade serous ovarian carcinomas and that its expression was already associated with the p53 proliferative signature, characteristic of premalignant type II EOC (Karst et al, 2011). This evidence concerns the gene STMN1 and ovarian serous carcinoma.